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doses. Further research is required to conﬁrm whether
such gender disparities persist, and, if so, whether they
are justiﬁed. Additional research linking quality with 
outcomes of care are necessary to determine their effects
on the outcomes of children with ADHD. In this way,
researchers and clinicians can work together to translate
ﬁndings into better patient care.
MH2
THE RELATIONSHIP OF ASTHMA AND
GENERALIZED ANXIETY DISORDER 
IN ADULTS
Marks AS, Kassulke JP,Allemand AM, Patel H
Caremark, Inc, Northbrook, IL, USA
OBJECTIVE: To determine the association between
asthma and generalized anxiety disorder for adults utiliz-
ing a PBM. METHODS: Adult participants (age 18–65
years) were retrospectively identiﬁed in Caremark’s PBM
database and assessed for asthma and generalized anxiety
disorder (GAD) from January 2002–September 2002.
Using pharmacy algorithms, asthmatic participants and
non-asthmatic participants were identiﬁed and compared
as having GAD where anxiety medication supply
exceeded 27 days. Sub-analysis of the asthma popula-
tion compared the utilization of speciﬁc drug classes to
the association of anxiety disorder. All populations were
compared using odds ratio analysis. RESULTS: A total 
of 4,238,840 participants (58.5% female) were evaluated
over the study period; 205,964 (4.86%) were identiﬁed
as being asthmatic (60.2% female, mean age 51.5 years,
std 15.7 years); 210,972 (4.98%) of the study population
were being treated with anti-anxiety medications; and
16,912 (0.4%) of the participants were treated with both.
Asthma was associated with a signiﬁcant increased 
likelihood of anxiety disorder (OR: 1.77; 95% CI: 1.74
to 1.80). Treatment with steroid inhalants and/or
leukotriene modulators was associated with a signiﬁcant
decrease in the likelihood of anxiety disorders among
asthmatics (OR: 0.89; 95% CI: 0.87 to 0.92). While treat-
ment with asthma combination medications was associ-
ated with a higher signiﬁcant increased likelihood of GAD
among asthmatics (OR: 2.22; 95% CI: 1.72 to 2.86).
CONCLUSION: These ﬁndings are consistent with pre-
viously published self-reported data showing an associa-
tion between asthma and GAD. In this study, participants
treated for asthma were found to be 77% more likely to
be treated for GAD than the general non-asthmatic 
population. Participants using steroid inhalants or
leukotriene modulators were 11% less likely to be treated
for GAD than other asthmatics. The use of asthma 
combination therapy was associated with 120%
increased likelihood of GAD treatment, possibly indicat-
ing the severity of the asthma condition is correlated to
an increased likelihood of GAD. Increased attention
needs to be placed on the management of anxiety as a
comorbidity of asthma.
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EVALUATING THE ECONOMIC
CONSEQUENCES OF EARLY SSRI DROP-OUTS
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1Applied Health Outcomes,Tampa, FL, USA; 2University of
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OBJECTIVES: HEDIS guidelines recommend patients
with depression remain on antidepressant therapy for a
minimum of six months to receive full clinical beneﬁt.
This study compared differences in healthcare costs based
upon length of SSRI therapy. METHODS: Continuously
eligible patients >18 years of age receiving SSRI therapy
diagnosed as having depression in a managed Medicaid
program from July 1, 1999 to December 31, 2000 were
eligible for study inclusion. Length of therapy was deﬁned
as total SSRI days supply acquired within six months of
the index date. Patients were placed into the following
cohorts based upon length of therapy or drug utilization
patterns: 1) <90 days; 2) 90–179 days; 3) >180 days; or
4) Switched/Augmented (SA). Differences in pharmaceu-
tical, professional, hospital and total healthcare costs
were evaluated across the four cohorts over a 1-year
follow-up period. RESULTS: There were 2250 patients
meeting all inclusion criteria. Only 34% of patients
received >180 days of therapy. While 24% had <90 days
of therapy, 21% had 90–179 days and 21% had evidence
of switching/augmentation. Demographic and back-
ground covariates were similar across all cohorts. As
expected, pharmaceutical charges increased as length 
of therapy increased, being highest in the SA cohort.
However, as length of therapy increased from <90 days
to >180 days, professional services and hospital charges
decreased by an average of $816 annually per patient.
Total monthly healthcare costs in the >180 day cohort
remained stable after at least 6 months of SSRI treatment
through the full 12-months that patients were followed.
CONCLUSIONS: Pharmaceutical costs increased as SSRI
length of therapy improves. However, healthcare costs
decreased due to reductions in hospital and professional
service charges for patients maintained on SSRIs for at
least the recommended six months of continuous therapy.
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DRUG UTILIZATION ANALYSIS OF THE SSRI
CLASS IN A MEDICAID HMO:THE FLUOXETINE
EXPERIENCE
Belazi D,Tegenu M
Keystone Mercy Health Plan, Philadelphia, PA, USA
OBJECTIVE: There is little research describing the effects
of the introduction of generic ﬂuoxetine to the SSRI
market. The purpose of this analysis is to examine uti-
lization of the SSRI class in a Pennsylvania Medicaid
HMO before and after the launch of ﬂuoxetine (generic)
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into the US marketplace. METHODS: Generic ﬂuoxetine
became available in August 2001. Pharmacy claims 
data from January 2000 to December 2002 were used 
to analyze utilization of the SSRI class (consisting of the
following: Celexa, Zoloft, Paxil, Effexor XR, Prozac, 
and ﬂuoxetine). Utilization data for each drug in the class
were separated into two group periods, pre- and post
introduction of generic ﬂuoxetine. The pre- and post
periods consisted of 19 and 17 months respectively. Uti-
lization of Prozac and ﬂuoxetine was used as a reference
to compare utilization of other drugs in the class. T-test
analysis was used to compare and show differences
between pre- and post-periods for each drug. RESULTS:
Prozac/ﬂuoxetine average monthly prescription utiliza-
tion for pre- and post-periods were 3434.16 and 4349.56
respectively (p < 0.001), which indicates an average
increase in monthly utilization by 27%. Celexa average
monthly utilization for pre- and post-periods were
1252.95 and 2848.4 respectively (p < 0.001), demon-
strating an increase in utilization by 127%. Effexor XR
average monthly utilization during pre- and post-periods
were 908.58 and 2084.38 respectively (p < 0.001), indi-
cating an increase of 129%. Paxil average monthly uti-
lization for pre- and post periods were 2834.9 and 4059.6
respectively (p < 0.001), indicating an increase of 43%.
Lastly, Zoloft’s average monthly utilization for pre- and
post periods were 3915.05 and 4615.88 respectively 
(p < 0.001), which resulted in an increase of 18%. 
CONCLUSION: In this managed care setting a signiﬁ-
cant increase in monthly utilization was seen for all drugs
with the exception of Zoloft.
NEUROLOGICAL DISEASES/DISORDERS
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COST-EFFECTIVENESS OF TOPIRAMATE AS
ADJUNCTIVE TREATMENT IN REFRACTORY
EPILEPSY—A PROBABILISTIC ASSESSMENT OF
TREATMENT STRATEGIES
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OBJECTIVES: Adopting new medical therapies is a
complex decision that must take into account many
factors, including differences in efﬁcacy, tolerability,
safety, and costs. Long-term comparative trials, especially
among newer antiepileptic drugs (AEDs), are lacking,
therefore decision models are needed to guide treatment
decisions. We aimed to develop an economic model of the
treatment of refractory epilepsy in the UK, and to assess
the cost-effectiveness of topiramate as adjunctive treat-
ment in refractory epilepsy compared to other newer
AEDs. METHODS: A Markov model was developed to
combine data from published clinical trials, cost-of illness
studies, epilepsy-related mortality surveys, and utility
studies. The expected costs and utilities associated with
possible treatment strategies (1st and 2nd line add-on
treatments) for newly diagnosed epilepsy patients with
partial seizures were calculated and compared. In those
patients requiring a second-line add-on, it was assumed
that the ﬁrst-line add-on treatment was stopped. A 
probabilistic analysis was undertaken and the cost-
effectiveness frontier mapped. RESULTS: First and
second-line adjunctive treatment with topiramate fol-
lowed by levetiracetam was the least costly add-on strat-
egy, and this strategy had the highest probability of being
cost-effective at currently accepted values of the ceiling
ratio (<£30,000/QALY). Levetiracetam ﬁrst-line, fol-
lowed by topiramate second-line generated additional
QALYs, but was more expensive, and was optimal only
if the ceiling ratio fell between £30,000 to £60,000/
QALY. Scenarios combining sequences of topiramate and
lamotrigine deliver a few additional QALYs at substan-
tial additional costs (became optimal only if the ceiling
ratio was >£60,000/QALY), while adjunctive treatment
with levetiracetam and lamotirigine are both more expen-
sive and generate less QALYs than the other scenarios,
therefore cannot be preferred. CONCLUSIONS: This
model suggests that topiramate ﬁrst-line adjunctive treat-
ment followed by levetiracetam second-line (or vice versa)
are cost-effective treatment strategies in patients with
partial seizures refractory to other treatments.
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AN ESTIMATE OF THE DIRECT COSTS OF
MIGRAINE IN THE UNITED STATES USING THE
MEDICAL EXPENDITURE PANEL SURVEY
Mychaskiw MA, Sankaranarayanan J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: As sales of anti-migraine prescription
medications increased by more than 10-fold between
1994 and 1999, it is important to quantify the impact on
the cost of migraine treatment. The objectives of this
study were to determine the direct costs of migraine in
the U.S. population and to stratify those costs by type of
medical care. METHODS: Retrospective analysis was
conducted of the 1999 Medical Expenditure Panel Survey.
The survey provided data from a nationally representa-
tive sample of 24,618 respondents and their medical care
and health insurance providers. Data utilized in this study
included medical conditions and use and payments for
medical care. Migraineurs were identiﬁed using ICD-9-
CM codes and direct costs were calculated using patient
and third-party payments for migraine related medical
events by type of medical care. Sample estimates were
projected to the population and 95% conﬁdence limits
were calculated using the Taylor expansion method.
RESULTS: Direct costs incurred per migraineur were
$293. Total direct costs of migraine were
$1,429,053,413. The highest proportion of these costs
